Xochipiltecatl-Muñoz DJ, López-Conde LR, Castellanos-Hernández H, Neave-Sánchez E, García-Villa PC, De la Cruz-Gutierrez SM, Velázquez-Macías RF

Language: Spanish
References: 6
Page: 64-67
PDF size: 136.31 Kb.

ABSTRACT

Cryosurgery has undergone numerous changes for the purpose of improving safety and reproducibility. Since the development of 17-G cryowaves and the use of argon gas as freezing agent, as well as the use of transrectal ultrasound as guide, thermal urethral catheter, and temperature monitoring transducers, cryosurgery has become a safe and more reproducible procedure.
Methods: A retrospective, cross-sectional study was carried out in which the case records of twenty-three patients having undergone prostatic cryoablation for prostate cancer at the Hospital Central Sur de Alta Especialidad of PEMEX Picacho were reviewed.
Results: Mean prostate specific antigen after procedure was 1.1 with SD ± 1.0. 65.72% of patients presented with negative biopsy after procedure, 13% with positive biopsy, and biopsy was not carried out on 21.7% of patients. Impotence presented in 87% of patients.
Discussion: In regard to oncological results, prostate specific antigen is the greatest evaluation factor in prostate cancer treatment results and therefore its levels have been established for surgery and radiotherapy. However, no studies have identified postcryoablation antigen.
Conclusions: Optimum prostate cancer management continues to be controversial. Given the high incidence of the disease and the morbidity associated with standard treatment options, there is continued interest on the part of both physicians and patients in minimally invasive options and cryotherapy is a viable option for low risk and intermediate risk cancer patients.

REFERENCES

1. Jones JS, Rewcastle JC, Donnelly BJ. Whole Gland Primary Prostate Cryoablation: Initial Result From the Cryo On-Line Data Registry. J Urol 2008;180:554-8.

2. Han KR, et al. Treatment of Organ Confined Prostate Cancer with Third Generation Cryosurgery: Preliminary Multicenter Experience. J Urol 2003;170(4Pt1):1126-30.

3. Gowardhan B, Thomas B, Asterling S. Cryosurgery for prostate cancer-experience with third-generation cryosurgery and novel developments in the field. European Urology Supplements. European Association of Urology 2007;6:516-20.

4. Levy DA, Pister LL, Jones JS. Primary Cryoablation Nadir Specific Antigen and Biochemical Failure. J Urol. 2009;182:931-7.

5. Bahn DK, et al. Targeted Cryoablation of the Prostate: 7-year Outcomes in the Primary Treatment of Prostate Cancer. Urology 2002;60(2Suppl1):3-11.

6. Onik GM, et al. Transrectal Ultrasound-Guided Percutaneous Radical Cryosurgical Ablation of the Prostate. Cancer 1993;72:1291-9.